Novo Nordisk A/S ($NVO) Stock Forecast: Down 5.2% Today

What is Novo Nordisk A/S?

Novo Nordisk (NVO) is a pharmaceutical company known for its focus on diabetes care and rare diseases. The market sentiment towards NVO was negative today.

Why is Novo Nordisk A/S going down?

NVO stock is down 5.2% on Oct 17, 2025 16:56

• NVO's stock price decreased by 1.11% after remarks from a prominent government official about reducing drug prices, with particular emphasis on weight-loss medications.
• The rise in Novo Nordisk's short interest is believed to have played a role in the downward movement, as some investors seem to be anticipating a further drop in the stock price.
• Despite finalizing a significant deal worth $2.1 billion to enhance its rare disease portfolio, concerns about weight-loss drugs and potential pricing restrictions took precedence in the market, resulting in the decline in NVO's stock.

NVO Price Chart

NVO Technical Analysis

NVO News

Novo, Lilly, Pfizer: Who Wins If Trump Slashes Prices? - Novo Nordisk ( NYSE:NVO ) , Eli Lilly ( NYSE:LLY ) , Pfizer ( NYSE:PFE )

President Donald Trump just dropped a political bomb into one of Wall Street's hottest trades.

https://www.benzinga.com/trading-ideas/long-ideas/25/10/48275949/novo-vs-lilly-vs-pfizer-who-wins-if-trump-slashes-the-price-of-weight-loss-drugs

Novo Nordisk ( NVO ) Suffers a Larger Drop Than the General Market: Key Insights

Novo Nordisk (NVO) concluded the recent trading session at $56.09, signifying a -1.11% move from its prior day's close.

https://www.zacks.com/stock/news/2770615/novo-nordisk-nvo-suffers-a-larger-drop-than-the-general-market-key-insights

Eli Lilly, Novo Nordisk, Hims & Hers Health Shares Move Lower After Trump Calls Out 'Fat-Loss Drugs' - Eli Lilly ( NYSE:LLY )

Shares of Eli Lilly And Co ( NYSE:LLY ) and Novo Nordisk A/S ( NYSE:NVO ) are moving lower in Thursday's after-hours session after President Donald Trump indicated that weight-loss drugs are going to come down in price.

https://www.benzinga.com/trading-ideas/movers/25/10/48265336/eli-lilly-novo-nordisk-hims-hers-health-shares-move-lower-after-trump-calls-out-fat-loss-dru

What's Driving the Market Sentiment Around Novo Nordisk AS? - Novo Nordisk ( NYSE:NVO )

Novo Nordisk AS's ( NYSE:NVO ) short interest as a percent of float has risen 9.41% since its last report. According to exchange reported data, there are now 31.46 million shares sold short, which is 0.93% of all regular shares that are available for trading.

https://www.benzinga.com/insights/short-sellers/25/10/48263086/whats-driving-the-market-sentiment-around-novo-nordisk-as

NVO, OMER Ink $2.1B Zaltenibart Deal to Bolster Rare Disease Portfolio

Novo Nordisk's $2.1 billion deal for Omeros' zaltenibart aims to strengthen its rare disease pipeline amid GLP-1 market headwinds.

https://www.zacks.com/stock/news/2770347/nvo-omer-ink-21b-zaltenibart-deal-to-bolster-rare-disease-portfolio

Trending Today

Sunrun Inc. ($RUN) Stock Forecast: Down 5.0% Today

Blink Charging Co. ($BLNK) Stock Forecast: Down 6.2% Today

Xerox Corporation ($XRX) Stock Forecast: Down 13.0% Today

AMC Entertainment Holdings Inc. Class A ($AMC) Stock Forecast: Down 5.3% Today

Intellia Therapeutics, Inc. ($NTLA) Stock Forecast: Down 9.8% Today

Kohl's Corporation ($KSS) Stock Forecast: Down 5.3% Today

Plug Power Inc. ($PLUG) Stock Forecast: Down 8.0% Today

FMC Corporation ($FMC) Stock Forecast: Down 45.1% Today

Enphase Energy Inc. ($ENPH) Stock Forecast: Down 6.4% Today

Upstart Holdings Inc. ($UPST) Stock Forecast: Down 5.4% Today

Novo Nordisk A/S Price History

30.06.2025 - NVO Stock was down 8.3%

• Novo Nordisk stock plummeted by 22% following the revision of its 2025 sales and profit forecasts due to challenges with GLP-1 drugs' uptake and increased competition.
• The company's profit warning has shaken investor confidence, contributing to the negative market sentiment.
• The stock's downward trajectory may persist as investors analyze the impact of the revised outlook and evaluate Novo Nordisk's competitive standing in the industry.

30.06.2025 - NVO Stock was down 6.8%

• The company revised its 2025 sales growth projection to 8-14%, down from the previous range of 13-21%, citing heightened competition in the U.S. GLP-1 market.
• Concerns over the performance of its weight-loss drug Wegovy contributed to the negative trend, with a profit warning adding to the downward pressure on the stock.
• The appointment of Maziar Mike Doustdar as the new President and CEO, starting on August 7, may have added to investor apprehensions regarding leadership changes.
• Comparisons with competitors, such as Eli Lilly's positive trial results for drug Jaypirca, could have shifted focus and investment interest away from Novo Nordisk, impacting market sentiment.

30.06.2025 - NVO Stock was down 6.4%

• Novo Nordisk saw a 22% drop in its stock price after revising downwards its projections for sales and profits by 2025. The decline was attributed to poor reception of its GLP-1 drugs and heightened market competition.
• Technical analysis of Novo Nordisk's stock reveals a bearish outlook post a profit warning related to its obesity drug Wegovy, indicating a negative trend for the company.
• The decrease in Novo Nordisk's stock value may be linked to its decision to lower its forecast for sales growth in 2025, citing increased competition in the U.S. GLP-1 market.
• The market response to Novo Nordisk's performance contrasts with positive developments from Eli Lilly, underscoring how industry rivalry and internal factors impact stock movements.

26.07.2025 - NVO Stock was down 5.0%

• Reports of at least 20 deviations linked to hair contamination and lack of thorough investigations may have raised concerns about product quality and safety standards, leading to a loss of investor confidence.
• The filing of multiple securities fraud class action lawsuits against Novo Nordisk could have created uncertainty and negative sentiment around the stock, impacting its price negatively.
• The revelation of a purchase of Novo Nordisk stock by Rep. Marjorie Taylor Greene might not have been enough to offset the overall bearish sentiment surrounding the company due to the other negative developments.

08.07.2025 - NVO Stock was up 5.2%

• The bullish movement in NVO stock could be attributed to the company's strong Q2 earnings beat despite revenue missing estimates, showcasing resilience in challenging market conditions.
• The increase in sales by 16% in Danish kroner and 18% at constant exchange rates reflects positive growth momentum for Novo Nordisk, boosting investor confidence.
• Despite facing US hurdles and competition for its GLP-1 drugs, the company's overall performance and revenue growth seem to have outweighed these challenges, leading to the bullish market movement.
• The trading activity by board members and executives might have also signaled confidence in the company's future prospects, further contributing to the positive sentiment surrounding NVO stock.

07.07.2025 - NVO Stock was up 7.2%

• NVO stock experienced a bullish movement likely due to the company's strong financial performance and sales growth in the first six months of 2025.
• Despite facing US hurdles and increased competition for its GLP-1 drugs, NVO's Q2 earnings beat expectations, showcasing resilience in the face of challenges.
• The class action lawsuit filed against NVO may have initially caused some uncertainty in the market, but the positive financial report overshadowed these concerns, leading to the bullish movement.
• The termination of the collaboration with Hims & Hers Health impacting their revenue per order for GLP-1 may have indirectly benefited NVO, as investors may have shifted focus towards the more promising performance of Novo Nordisk.

07.07.2025 - NVO Stock was up 5.6%

• Novo Nordisk's strong bullish movement today is linked to their impressive sales growth in the first six months of 2025. There was a 16% increase in Danish kroner and an 18% rise at constant exchange rates.
• Despite challenges in the US market and increased competition for their GLP-1 drugs, the company's Q2 earnings surpassed expectations. This likely boosted investor confidence in their long-term growth.
• The termination of a collaboration with Hims & Hers Health led to a decline in HIMS shares, indirectly benefiting Novo Nordisk as investor focus possibly shifted to the pharmaceutical giant's positive performance.
• While facing an ongoing class action lawsuit, Novo Nordisk's strong financial results seem to have outweighed any legal concerns, leading to a rise in the stock price.

18.08.2025 - NVO Stock was up 5.9%

• Novo Nordisk's stock surged today due to positive results from its weight-loss pill, Wegovy, which demonstrated a significant reduction in cardiovascular event risk compared to a competitor's treatment.
• The company's next-generation obesity treatment candidate, cagrilintide, also showed promising results in a phase III study, further boosting investor confidence.
• Analyst sentiment and upgrade momentum for Novo Nordisk increased, fueled by the successful clinical outcomes and the potential growth narrative reset in the weight-loss market.
• Despite facing FDA scrutiny alongside other companies in the weight-loss treatment sector, Novo Nordisk's strong performance and positive data overshadowed any regulatory concerns, leading to a bullish market movement.

17.09.2025 - NVO Stock was down 5.2%

• NVO stock closed lower at $56.09, down by -1.11% from the previous day's close.
• President Trump's comments on weight-loss drugs potentially lowering in price may have negatively impacted NVO and Eli Lilly's stock prices.
• The increase in Novo Nordisk's short interest could have added selling pressure on the stock, contributing to the bearish movement.
• The $2.1 billion deal between NVO and Omeros to bolster their rare disease portfolio might not have been well received by investors, possibly due to concerns about the impact on NVO's financials or strategic direction.

17.09.2025 - NVO Stock was down 5.2%

• NVO's stock price decreased by 1.11% after remarks from a prominent government official about reducing drug prices, with particular emphasis on weight-loss medications.
• The rise in Novo Nordisk's short interest is believed to have played a role in the downward movement, as some investors seem to be anticipating a further drop in the stock price.
• Despite finalizing a significant deal worth $2.1 billion to enhance its rare disease portfolio, concerns about weight-loss drugs and potential pricing restrictions took precedence in the market, resulting in the decline in NVO's stock.

01.09.2025 - NVO Stock was up 5.2%

• Novo Nordisk's upward movement could be attributed to its expansion beyond current obesity treatments like Wegovy and Ozempic with next-generation candidates, signaling potential for market leadership in the obesity sector.
• The announcement of a class action lawsuit by the Portnoy Law Firm on behalf of NVO investors during a specific period may have initially caused some uncertainty, but the market appears to have reacted positively to other growth prospects.
• Despite fluctuations in related stocks such as Inventiva and Electronic Arts, Novo Nordisk stood out with its positive momentum, demonstrating resilience amid wider market changes.
• Investor confidence in Novo Nordisk may have been bolstered by the limited impact of the lawsuit, leading to increased buying interest and driving the stock price up.

18.08.2025 - NVO Stock was up 5.2%

• The bullish movement in NVO stock can be attributed to the promising Phase III data for its next-generation obesity treatment candidate, cagrilintide, which showed significant weight loss in a clinical study.
• Additionally, the real-world study demonstrating Wegovy's superior cardiovascular risk reduction compared to tirzepatide could have further boosted investor confidence in Novo Nordisk's innovative treatments.
• The potential FDA approval for a high-dose version of Wegovy also signals growth opportunities for Novo Nordisk in the weight-loss market, attracting more investors to the stock.
• Despite recent challenges and a significant decline in stock value, the positive developments in Novo Nordisk's product pipeline seem to have reignited investor optimism and sparked today's bullish momentum.